5Reimer P, Fischbach W, Goebeler ME, et al. Decreased frequency of HLA-B35 in patients with gastric MALT lymphoma. Ann Hematol, 2004, 83:232-236.
6Quintero E, Pizarro MA, Rodrigo L, et al. Association of Helicobacter pylori-related distal gastric cancer with the HLA class Ⅱ gene DQB10602 and cagA strains in a southern European population. Helicobacter, 2005, 10:12-21.
7Santolaria S, Barrios Y, Benito R, et al. Helicobacter pylori and immunogenetic factors of the host: relevance of the HLADQA1 0102 and * 0301 alleles in peptic ulcer. Gastroenterol Hepatol, 2001, 24:117-121.
8Moayyedi P, Soo S, Deeks J, et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group. BMJ ,2000,321: 659-664.
9TULASAY Z, KRYSZEWSKI A, DITE P, et al. One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients duodenal ulcer disease[ J]. Eur J Gastroenterol Hepatol.2001,13 : 1457.
10KIM BG, LEE DH, YE BD, et al. Comparison of 7-day and 14-day pmton pump inhibitor-containing triple therapy for Helicobacter pylori eradication : neither treatment duration provides acceptable eradi- cation rate in Korea[ J]. Helicobacter,2007,12( 1 ) :31.
9Smith B R, Wilson S E. Impact of nonresective operations for compli-cated peptic ulcer disease in a high-risk population [ J ]. Am Surg,2010,76(10): 1143 -1146.
10Yeomans N D. The ulcer sleuths : The search for the cause of peptic ul-cers[ J] . J Gastroenterol Hepatol, 2011,26( Suppl 1) : 35 -41.
